Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma
Brief Summary: Alveolar soft part sarcoma (ASPS), a rare subset of STS (<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.